TrovaGene (NASDAQ:TROV) posted its quarterly earnings data on Thursday. The medical research company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.13, Fidelity Earnings reports. TrovaGene had a negative return on equity of 149.88% and a negative net margin of 3,424.46%. The business had revenue of $0.05 million for the quarter.
Shares of TROV traded down $0.03 during trading hours on Friday, hitting $1.71. The stock had a trading volume of 179,500 shares, compared to its average volume of 870,989. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.20 and a current ratio of 3.20. The firm has a market cap of $11.07 million, a P/E ratio of -0.21 and a beta of 0.25. The company’s fifty day simple moving average is $1.49 and its 200 day simple moving average is $2.24. TrovaGene has a 12-month low of $0.88 and a 12-month high of $9.65.
Several equities research analysts have recently issued reports on TROV shares. Noble Financial restated a “buy” rating and set a $23.00 price objective on shares of TrovaGene in a report on Wednesday, October 2nd. Maxim Group restated a “buy” rating and set a $6.00 price objective on shares of TrovaGene in a report on Thursday, October 3rd.
Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.
Featured Story: What is range trading?
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.